And, how does Ebola hide in the brain?

Get full access to Reuters.com for just $1/week. Subscribe now.

 

Health Rounds

Health Rounds

By Nancy Lapid, Health Science Editor

Hello Health Rounds readers! Today we report on a new type of drug being developed to heal injured heart tissue that could work for kidneys as well. We also report on new understanding of how the Ebola virus may persist in the body for months, and a troubling spread of drug-resistant bacteria outside of hospitals.

In U.S. news: the Trump administration seeks to let Kennedy pick vaccine panel members; ICE immigrant detention center death rate more than doubles under Trump; as menopause treatment demand grows, progesterone supplies tighten; FDA warns 25 telehealth companies over claims on compounded weight-loss drugs; health department proposes testosterone therapy label updates and announces $700 million to combat mental health, addiction, and homelessness; and US judge limits enforcement of Idaho's transgender bathroom access law.

Ebola updates: Congo says number of confirmed cases rises to 896; advocacy groups urge U.S. to share experimental drug for outbreak trials;  US CDC activates $107 million in emergency funding; EU pledges €493 million in vaccines, treatment and health aid; a month after WHO declares international emergency, Congo response is strained; and donors have paid less than 10% of pledges, Africa CDC says.

Also: Cholera death toll rises in northeast Nigeria; UAE sets minimum social media age at 15, mandates age checks; Canadian committee recommends against euthanasia solely for mental illness; and Italy's privacy watchdog fines Emirates over handling of passenger health data.

 

Industry Updates

  • Merck pneumococcal vaccine wins US approval for high-risk children, teens.
  • Moderna mRNA flu vaccine backed by FDA advisers.
  • Aurobindo Pharma must divest from four drug products to complete acquistion of Lannett.
  • GSK oral antibiotic wins US approval for drug-resistant UTIs.
  • Jazz Pharma, AbCellera ink antibody deal worth up to $876 million.
  • KKR eyes at least $1 billion stake in Medicover's India hospital arm.
  • Novocure brain cancer therapy fails in late-stage trial.
 
 

What pet owners need to know about New World screwworm

REUTERS/Kaylee Greenlee

Screwworm, a parasitic fly whose larvae feed on the flesh of living animals, is back in the U.S. for the first time since the 1970s, posing a threat to livestock, wildlife and pets. Here's what veterinarians say pet owners, particularly those near the U.S.-Mexico border, need to know.

 

Study Rounds

Experimental heart drug shows promise in kidneys

 

An experimental drug for healing heart tissue recently green-lighted for pilot trials in humans may have promise for healing kidney tissues as well, lab experiments suggest.

The drug, AD-NP1, which is under development at UCLA, is designed to help avoid heart failure after a heart attack by blocking the protein ENPP1 that disrupts healing and prevents full recovery.

When UCLA researchers examined kidney biopsies from people with chronic kidney disease, they found this same protein at higher levels than in healthy tissues.

When they induced kidney injuries in normal mice and mice with ENPP1 blocked by genetic engineering, all of the animals initially showed some damage. But weeks later, the mice without ENPP1 had enhanced kidney repair, reduced scarring, and improved kidney function, the researchers reported in Cell Stem Cell.

The researchers then induced kidney damage in normal mice and administered AD-NP1. One week later, the mice showed improved kidney function and healing.

The ENPP1 protein interferes with critical pathways that are needed for a cell to derive energy, study leader Arjun Deb of UCLA said in a statement.

"We found that the same mechanisms we observed in the heart were also applicable in the kidney," Deb said.

Development of the first-in-class drug has been supported by grants from the U.S. National Institutes of Health, the Department of Defense, and the California Institute for Regenerative Medicine.

 

Scientists learn how Ebola survives in the brain for months

New lab experiments are shedding light on how the Ebola virus can survive unnoticed in the body for months or even years after initial infection, with the potential to trigger a relapse.

Infectious Ebola virus has been detected in semen for months or even a year after infection, and it can also persist in the central nervous system, particularly the brain, researchers explain in discussing their study published in Nature Microbiology.

That’s because testicles – the source of semen – and the central nervous system are considered to be “immune-privileged,” meaning the immune system reacts in a weakened and controlled manner in these areas in order to protect sensitive tissue. As a result, it cannot always eliminate the virus completely.

To learn more, researchers programmed human stem cells to grow into so-called cerebral organoids, spherical brain-like structures consisting of central nervous system cells.

The Ebola virus infected multiple cell types in the cerebral organoids and could replicate for up to 120 days, they found.

The virus was able to spread in the cerebral organoids in two ways: directly from an infected cell to a neighboring cell, and by budding from the host cell, which is the classical way the virus spreads.

“These cerebral organoids enable us to investigate in detail the mechanisms that Ebola virus and other filoviruses use to persist in the human central nervous system,” study leader Lina Widerspick of the Bundeswehr Institute of Microbiology in Munich said in a statement.

“Through experiments in this model system, we can gain insights that help us improve our understanding of the long-term effects of persistence, like the severe and sometimes fatal inflammation seen in Ebola virus disease survivors with meningoencephalitis.”

Studying the infected organoids, the researchers discovered genome mutations that may be helping the virus to lurk undetected, including some mutations that had not previously been described in Ebola survivors.

They called for further studies, particularly into less well understood strains, such as the Bundibugyo virus causing the current outbreak in Africa.

 

Read more about Ebola on Reuters.com